{"title":"Correction to “Clinical Pharmacology and Translational Considerations in the Development of CRISPR-Based Therapies”","authors":"","doi":"10.1002/cpt.3592","DOIUrl":null,"url":null,"abstract":"<p>Abdelhady, A.M., Phillips, J.A., Xu, Y. & Stroh, M. Clinical Pharmacology and Translational Considerations in the Development of CRISPR-Based Therapies. <i>Clin. Pharmacol. Ther</i>., <b>114</b>, 591–603 (2023), https://doi.org/10.1002/cpt.3000.</p><p>On page 593, the sentence, “Accordingly, a complete bioanalytical characterization of a novel nanoparticle formulation can entail multiple analytes and is a consideration not only for characterization of the PKs and distribution of CRISPR/Cas9-based therapy, but also PK/PD relationships.” Should refer to references 12 and 13 in the reference list.</p><p>On page 594, the sentence, “The patisiran LNPis comprised of four components, including ionizable amino lipidDLin-MC3-DMA and a polyethylene glycol (PEG) lipid 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (in addition to1,2-distearoyl-sn-glycero-3-phosphocholine and cholesterol).” Should refer to reference 12 in the reference list.</p><p>We apologize for this error.</p>","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":"117 4","pages":""},"PeriodicalIF":5.5000,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cpt.3592","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3592","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Abdelhady, A.M., Phillips, J.A., Xu, Y. & Stroh, M. Clinical Pharmacology and Translational Considerations in the Development of CRISPR-Based Therapies. Clin. Pharmacol. Ther., 114, 591–603 (2023), https://doi.org/10.1002/cpt.3000.
On page 593, the sentence, “Accordingly, a complete bioanalytical characterization of a novel nanoparticle formulation can entail multiple analytes and is a consideration not only for characterization of the PKs and distribution of CRISPR/Cas9-based therapy, but also PK/PD relationships.” Should refer to references 12 and 13 in the reference list.
On page 594, the sentence, “The patisiran LNPis comprised of four components, including ionizable amino lipidDLin-MC3-DMA and a polyethylene glycol (PEG) lipid 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (in addition to1,2-distearoyl-sn-glycero-3-phosphocholine and cholesterol).” Should refer to reference 12 in the reference list.
期刊介绍：
Clinical Pharmacology & Therapeutics (CPT) is the authoritative cross-disciplinary journal in experimental and clinical medicine devoted to publishing advances in the nature, action, efficacy, and evaluation of therapeutics. CPT welcomes original Articles in the emerging areas of translational, predictive and personalized medicine; new therapeutic modalities including gene and cell therapies; pharmacogenomics, proteomics and metabolomics; bioinformation and applied systems biology complementing areas of pharmacokinetics and pharmacodynamics, human investigation and clinical trials, pharmacovigilence, pharmacoepidemiology, pharmacometrics, and population pharmacology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
